1 November 2022 false Taxfiler 2024.1 13694696business:PrivateLimitedCompanyLtd2022-11-012023-10-31 136946962022-10-31 136946962022-11-012023-10-31 13694696business:AuditExemptWithAccountantsReport2022-11-012023-10-31 13694696business:FilletedAccounts2022-11-012023-10-31 136946962023-10-31 13694696business:Director12022-11-012023-10-31 13694696business:Director22022-11-012023-10-31 13694696business:Director32022-11-012023-10-31 13694696business:Director42022-11-012023-10-31 13694696business:RegisteredOffice2022-11-012023-10-31 136946962022-10-31 13694696core:WithinOneYear2023-10-31 13694696core:WithinOneYear2022-10-31 13694696core:AfterOneYear2023-10-31 13694696core:AfterOneYear2022-10-31 13694696core:ShareCapitalcore:PreviouslyStatedAmount2023-10-31 13694696core:ShareCapitalcore:PreviouslyStatedAmount2022-10-31 13694696core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-10-31 13694696core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2022-10-31 13694696core:PreviouslyStatedAmount2023-10-31 13694696core:PreviouslyStatedAmount2022-10-31 13694696business:SmallEntities2022-11-012023-10-31 13694696countries:EnglandWales2022-11-012023-10-31 13694696core:Goodwill2022-10-31 13694696core:Goodwill2023-10-31 13694696core:Goodwill2022-11-012023-10-31 13694696core:LandBuildings2022-10-31 13694696core:LandBuildings2023-10-31 13694696core:AfterOneYear2022-11-012023-10-31 136946962021-11-012022-10-31 iso4217:GBP xbrli:pure
Company Registration No. 13694696 (England and Wales)
NOVEL SWAN PHARMA LIMITED Unaudited accounts for the year ended 31 October 2023
NOVEL SWAN PHARMA LIMITED Unaudited accounts Contents
Page
- 2 -
NOVEL SWAN PHARMA LIMITED Company Information for the year ended 31 October 2023
Directors
Mr. Chun Hin Wong Mr. Yuen Fung Lam Mr. Him Shuen Chung Dr. Philip Majoe
Company Number
13694696 (England and Wales)
Registered Office
178 CAERAU ROAD MAESTEG CF34 0PD WALES
Accountants
Kimee & Associates Office T, First Floor, Raydean House, 15-17 Western Parade, Great North Road Barnet, London EN5 1AH
- 3 -
NOVEL SWAN PHARMA LIMITED Statement of financial position as at 31 October 2023
2023 
2022 
Notes
£ 
£ 
Fixed assets
Intangible assets
1,148,000 
1,209,500 
Tangible assets
100,000 
100,000 
1,248,000 
1,309,500 
Current assets
Debtors
- 
140,000 
Cash at bank and in hand
36,339 
- 
36,339 
140,000 
Creditors: amounts falling due within one year
(1,500)
- 
Net current assets
34,839 
140,000 
Total assets less current liabilities
1,282,839 
1,449,500 
Creditors: amounts falling due after more than one year
(1,337,118)
(1,466,045)
Net liabilities
(54,279)
(16,545)
Capital and reserves
Called up share capital
100 
100 
Profit and loss account
(54,379)
(16,645)
Shareholders' funds
(54,279)
(16,545)
For the year ending 31 October 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 17 April 2024 and were signed on its behalf by
Mr. Him Shuen Chung Director Company Registration No. 13694696
- 4 -
NOVEL SWAN PHARMA LIMITED Notes to the Accounts for the year ended 31 October 2023
1
Statutory information
NOVEL SWAN PHARMA LIMITED is a private company, limited by shares, registered in England and Wales, registration number 13694696. The registered office is 178 CAERAU ROAD, MAESTEG, CF34 0PD, WALES.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Intangible fixed assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
4
Intangible fixed assets
Goodwill 
£ 
Cost
At 1 November 2022
1,230,000 
At 31 October 2023
1,230,000 
Amortisation
At 1 November 2022
20,500 
Charge for the year
61,500 
At 31 October 2023
82,000 
Net book value
At 31 October 2023
1,148,000 
At 31 October 2022
1,209,500 
- 5 -
NOVEL SWAN PHARMA LIMITED Notes to the Accounts for the year ended 31 October 2023
5
Tangible fixed assets
Land & buildings 
£ 
Cost or valuation
At cost 
At 1 November 2022
100,000 
At 31 October 2023
100,000 
Depreciation
At 31 October 2023
- 
Net book value
At 31 October 2023
100,000 
At 31 October 2022
100,000 
6
Debtors
2023 
2022 
£ 
£ 
Amounts falling due within one year
Trade debtors
- 
140,000 
7
Creditors: amounts falling due within one year
2023 
2022 
£ 
£ 
Accruals
1,500 
- 
8
Creditors: amounts falling due after more than one year
2023 
2022 
£ 
£ 
Bank loans
1,285,502 
1,341,329 
Loans from directors
51,616 
124,716 
1,337,118 
1,466,045 
Directors's Loan £124,716 Barclays Business Loan £1,341,329
9
Average number of employees
During the year the average number of employees was 0 (2022: 0).
- 6 -